0001171843-26-002539
SEC filingNanobiotix S.A. announced new preclinical data demonstrating that its Nanoprimer platform, when administered prior to LNP-delivered DNA immunotherapy in mice, increased systemic bioavailability, reduced hepatic toxicity, and attenuated cGAS-STING–mediated inflammation.
This 6-K filing reports preclinical findings—not clinical or financial results—focused on Nanobiotix’s Nanoprimer platform used in sequence with LNP-delivered recombinant DNA immunotherapy. The data, generated in collaboration with Earli and presented at AACR 2026, address well-documented pharmacokinetic limitations of LNP-based therapies: rapid MPS-mediated hepatic clearance, low systemic exposure, and cGAS-STING–driven acute inflammation. In a mouse model, Nanoprimer pre-treatment transiently occupied hepatic clearance pathways, resulting in measurable improvements across three mechanistic endpoints: reduced liver exposure/toxicity, increased circulating LNP-DNA levels, and dampened inflammatory signaling. Critically, the tested LNP-DNA was already engineered for extrahepatic delivery—suggesting Nanoprimer may provide additive optimization rather than foundational correction. While these are non-human, non-clinical results, they represent a functional proof-of-concept for Nanoprimer as a therapeutic companion platform applicable across multiple next-generation modalities (e.g., RNA, gene therapies). No timelines, clinical plans, partnership terms, or financial implications are disclosed; the release serves primarily to de-risk the platform’s biological mechanism and support ongoing external collaboration efforts and internal pipeline advancement.